Hualan Biological Engineering Inc.
002007
Rang în acțiuni
#4386
Hualan Biological Engineering Inc. operates as a biopharmaceutical company,... Hualan Biological Engineering Inc. operates as a biopharmaceutical company, specializing in the research, development, production, and commercialization of a diverse portfolio of medical products within the People's Republic of China. Its offerings span plasma-derived therapies, various viral and bacterial vaccines, recombinant proteins, and other advanced biologics. The company's extensive range of plasma products includes essential components like human albumin, a broad spectrum of human immunoglobulins (such as intravenous, rabies, hepatitis B, and tetanus formulations), and vital coagulation factors like human prothrombin complex and factor VIII. Hualan also provides specialized solutions such as lyophilized human thrombin for external use and surgical fibrin glue. In its vaccine division, Hualan offers critical immunizations, including several influenza vaccines (e.g., split virus, A H1N1, and quadrivalent forms), recombinant hepatitis B vaccine, and ACYW135 meningococcal polysaccharide vaccine. The company actively pursues strategic collaborations with key scientific organizations, most notably the Chinese Academy of Sciences, as well as other esteemed research institutes and enterprises. Established in 1992, Hualan Biological Engineering Inc. is headquartered in Xinxiang, People's Republic of China.
Preț acțiune
$1.92
Capitalizare de piață
$3.50B
Schimbare (1 zi)
-1.39%
Schimbare (1 an)
-19.45%
Țară
CN
Tranzacționează Hualan Biological Engineering Inc. (002007)
Categorie
Healthcare
Raport P/S pentru Hualan Biological Engineering Inc. (002007)
Raport P/S la data de October 2026 TTM: 5.36
Conform celor mai recente rapoarte financiare și prețului acțiunilor Hualan Biological Engineering Inc., raportul P/S actual (TTM) este 5.36. La sfârșitul anului 2024, compania avea un P/S de 7.02.
Istoricul raportului P/S pentru Hualan Biological Engineering Inc. din 2001 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 5.36 | -11.26% |
| 2025 | 6.04 | -14.05% |
| 2024 | 7.02 | -7.05% |
| 2023 | 7.56 | -17.31% |
| 2022 | 9.14 | -23.59% |
| 2021 | 11.96 | -21.76% |
| 2020 | 15.29 | 15.15% |
| 2019 | 13.28 | 53.61% |
| 2018 | 8.64 | -21.68% |
| 2017 | 11.04 | -35.77% |
| 2016 | 17.18 | -1.12% |
| 2015 | 17.38 | 11.70% |
| 2014 | 15.56 | 4.91% |
| 2013 | 14.83 | 19.00% |
| 2012 | 12.46 | -18.28% |
| 2011 | 15.25 | -31.02% |
| 2010 | 22.10 | 35.18% |
| 2009 | 16.35 | -8.44% |
| 2008 | 17.86 | -46.00% |
| 2007 | 33.07 | 232.46% |
| 2006 | 9.95 | 356.58% |
| 2005 | 2.18 | 14.63% |
| 2004 | 1.90 | -24.46% |
| 2003 | 2.52 | -31.73% |
| 2002 | 3.69 | -27.97% |
| 2001 | 5.12 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | 86.99% |
US
|
|
| 40.55 | 656.57% |
US
|
|
| 4.19 | -21.81% |
AU
|
|
| 10.44 | 94.84% |
NL
|
|
| 4.52 | -15.70% |
BE
|
